$VXRT
Vaxart, Inc. Stock $vxrt

$vxrt Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000143774921011133 Filed on May 06, 2021

Income Statement

Concept	2021 Q1	2020 Q4	2020 Q1
Revenue	$506.0K	$356.0K	$2.902M
YoY Change	-82.56%	-90.91%	-46.33%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.940M	$5.130M	$1.990M
YoY Change	198.49%	285.71%	-1.97%
% of Gross Profit
Research & Development	$10.07M	$8.590M	$1.542M
YoY Change	553.24%	161.09%	-59.73%
% of Gross Profit
Depreciation & Amortization	$75.00K	$860.0K	$19.00K
YoY Change	294.74%	14.67%	-85.38%
% of Gross Profit
Operating Expenses	$16.02M	$13.72M	$3.596M
YoY Change	345.41%	43.75%	-38.58%
Operating Profit	-$15.51M		-$694.0K
YoY Change	2135.01%		54.91%
Interest Expense	$9.000K	$10.00K
YoY Change		-66.67%
% of Operating Profit
Other Income/Expense, Net	-$470.0K	-$470.0K	-$450.0K
YoY Change	4.44%	-7.84%	-29.8%
Pretax Income	-$15.97M	-$13.83M	-$1.144M
YoY Change	1295.89%	122.71%	5.05%
Income Tax	$38.00K	$30.00K	$153.0K
% Of Pretax Income
Net Earnings	-$16.01M	-$13.86M	-$1.297M
YoY Change	1134.16%	116.27%	-3.14%
Net Earnings / Revenue	-3163.44%	-3893.54%	-44.69%
Basic Earnings Per Share	-$0.14
Diluted Earnings Per Share	-$138.7K	-$126.2K	-$21.42K
COMMON SHARES
Basic Shares Outstanding	115.4M	109.5M	70.73M
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q1	2020 Q4	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$170.7M	$126.9M	$29.90M
YoY Change	470.9%	839.78%	255.95%
Cash & Equivalents	$157.3M	$126.9M	$29.86M
Short-Term Investments	$13.40M	$0.00
Other Short-Term Assets	$4.000M	$1.300M	$1.000M
YoY Change	300.0%	160.0%	-16.67%
Inventory
Prepaid Expenses
Receivables	$700.0K	$334.0K	$2.663M
Other Receivables	$500.0K	$300.0K	$0.00
Total Short-Term Assets	$175.4M	$128.5M	$33.67M
YoY Change	421.08%	630.37%	120.75%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.245M	$1.480M	$191.0K
YoY Change	1075.39%	604.76%	-87.75%
Goodwill		$0.00
YoY Change
Intangibles	$14.93M	$15.36M	$16.66M
YoY Change	-10.4%	-10.13%	-10.59%
Long-Term Investments	$6.600M
YoY Change
Other Assets	$369.0K	$372.0K	$138.0K
YoY Change	167.39%	163.83%	32.69%
Total Long-Term Assets	$30.45M	$24.05M	$18.90M
YoY Change	61.1%	23.76%	-10.26%
TOTAL ASSETS
Total Short-Term Assets	$175.4M	$128.5M	$33.67M
Total Long-Term Assets	$30.45M	$24.05M	$18.90M
Total Assets	$205.9M	$152.6M	$52.56M
YoY Change	291.65%	312.03%	44.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.638M	$2.133M	$793.0K
YoY Change	484.87%	150.35%	-6.6%
Accrued Expenses	$3.176M	$4.799M	$4.280M
YoY Change	-25.79%	5.13%	147.83%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$1.800M	$2.800M	$1.500M
YoY Change	20.0%		-11.76%
Total Short-Term Liabilities	$11.64M	$11.76M	$7.441M
YoY Change	56.46%	28.22%	-12.97%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Other Long-Term Liabilities	$122.0K	$109.0K	$18.00K
YoY Change	577.78%	505.56%	0.0%
Total Long-Term Liabilities	$122.0K	$109.0K	$18.00K
YoY Change	577.78%	505.56%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.64M	$11.76M	$7.441M
Total Long-Term Liabilities	$122.0K	$109.0K	$18.00K
Total Liabilities	$29.63M	$29.18M	$21.27M
YoY Change	39.3%	21.17%	-10.37%
SHAREHOLDERS EQUITY
Retained Earnings	-$164.9M	-$148.9M	-$118.0M
YoY Change	39.79%	27.62%	18.72%
Common Stock	$341.1M	$272.3M	$149.3M
YoY Change	128.56%	110.08%	33.34%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$176.2M	$123.4M	$31.29M
YoY Change
Total Liabilities & Shareholders Equity	$205.9M	$152.6M	$52.56M
YoY Change	291.65%	312.03%	44.77%

Cashflow Statement

Concept	2021 Q1	2020 Q4	2020 Q1
OPERATING ACTIVITIES
Net Income	-$16.01M	-$13.86M	-$1.297M
YoY Change	1134.16%	116.27%	-3.14%
Depreciation, Depletion And Amortization	$75.00K	$860.0K	$19.00K
YoY Change	294.74%	14.67%	-85.38%
Cash From Operating Activities	-$16.59M	-$10.77M	-$3.208M
YoY Change	417.21%	184.17%	-31.06%
INVESTING ACTIVITIES
Capital Expenditures	$615.0K	-$900.0K	$4.000K
YoY Change	15275.0%	8900.0%	-99.28%
Acquisitions
YoY Change
Other Investing Activities	-$19.94M	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$20.56M	-$900.0K	-$1.000K
YoY Change	2055800.0%	8900.0%	-99.82%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$65.71M		$9.175M
YoY Change	616.21%		267.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$67.59M	5.100M	$19.54M
YoY Change	245.88%	-328.7%	820.49%
NET CHANGE
Cash From Operating Activities	-$16.59M	-10.77M	-$3.208M
Cash From Investing Activities	-$20.56M	-900.0K	-$1.000K
Cash From Financing Activities	$67.59M	5.100M	$19.54M
Net Change In Cash	$30.44M	-6.570M	$16.33M
YoY Change	86.38%	8.96%	-629.95%
FREE CASH FLOW
Cash From Operating Activities	-$16.59M	-$10.77M	-$3.208M
Capital Expenditures	$615.0K	-$900.0K	$4.000K
Free Cash Flow	-$17.21M	-$9.870M	-$3.212M
YoY Change	435.71%	161.11%	-38.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	117963912
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	122268453
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	117963912
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	110271093
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	110271093
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2020Q1	vxrt	Impairment Of Property And Equipment ImpairmentOfPropertyAndEquipment	0	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	0	USD
CY2021Q1	vxrt	Contract With Customer Asset Revenue Recognized ContractWithCustomerAssetRevenueRecognized	0	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	USD
CY2021Q1	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	0	USD
CY2021Q1	vxrt	Lessee Operating Lease Number Of Leases LesseeOperatingLeaseNumberOfLeases	5	pure
CY2021Q1	vxrt	Lessee Operating Lease Number Of Rightofuse Leases Subleased LesseeOperatingLeaseNumberOfRightofuseLeasesSubleased	1	pure
CY2021Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2021Q1	us-gaap	Longterm Purchase Commitment Period LongtermPurchaseCommitmentPeriod	P18M
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	157311000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126870000	USD
CY2021Q1	us-gaap	Short Term Investments ShortTermInvestments	13385000	USD
CY2020Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	700000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	334000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4024000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1327000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	175420000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	128531000	USD
CY2021Q1	us-gaap	Long Term Investments LongTermInvestments	6554000	USD
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2245000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1480000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6350000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6838000	USD
CY2021Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	14928000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	15361000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	369000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	372000	USD
CY2021Q1	us-gaap	Assets Assets	205866000	USD
CY2020Q4	us-gaap	Assets Assets	152582000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	4638000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2133000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2006000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2052000	USD
CY2021Q1	vxrt	Liability Related To Sale Of Future Royalties Current LiabilityRelatedToSaleOfFutureRoyaltiesCurrent	1822000	USD
CY2020Q4	vxrt	Liability Related To Sale Of Future Royalties Current LiabilityRelatedToSaleOfFutureRoyaltiesCurrent	2779000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3176000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4799000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	11642000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11763000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4628000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	5156000	USD
CY2021Q1	vxrt	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	13239000	USD
CY2020Q4	vxrt	Liability Related To Sale Of Future Royalties Noncurrent LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent	12150000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	122000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	109000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	29631000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	29178000	USD
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	12000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	11000	USD
CY2021Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	341116000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	272274000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-164888000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-148881000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	176235000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	123404000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	205866000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	152582000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	506000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	2902000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10073000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1542000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	96000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-1297000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	31293000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5944000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1990000	USD
CY2021Q1	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2020Q1	us-gaap	Restructuring Charges RestructuringCharges	64000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	16017000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	3596000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-15511000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-694000	USD
CY2021Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	9000	USD
CY2020Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	41000	USD
CY2021Q1	vxrt	Noncash Interest Expense On Liability NoncashInterestExpenseOnLiability	466000	USD
CY2020Q1	vxrt	Noncash Interest Expense On Liability NoncashInterestExpenseOnLiability	491000	USD
CY2021Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1000	USD
CY2020Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-15969000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-1144000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	38000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	153000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-16007000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-1297000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	115422628
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	60677145
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-16007000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-1297000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-5000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16012000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1297000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	123404000	USD
CY2021Q1	vxrt	Stock Issued During Period Value Exercise Of Common Stock Warrants StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants	1649000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	231000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1251000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-5000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-16007000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	176235000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	12952000	USD
CY2020Q1	vxrt	Stock Issued During Period Value Exercise Of Common Stock Warrants StockIssuedDuringPeriodValueExerciseOfCommonStockWarrants	10349000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	18000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-16007000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-1297000	USD
CY2021Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	996000	USD
CY2020Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	580000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1251000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	96000	USD
CY2021Q1	vxrt	Noncash Interest Expense On Liability NoncashInterestExpenseOnLiability	466000	USD
CY2020Q1	vxrt	Noncash Interest Expense On Liability NoncashInterestExpenseOnLiability	491000	USD
CY2021Q1	vxrt	Noncash Revenue Related To Sale Of Future Royalties NoncashRevenueRelatedToSaleOfFutureRoyalties	334000	USD
CY2020Q1	vxrt	Noncash Revenue Related To Sale Of Future Royalties NoncashRevenueRelatedToSaleOfFutureRoyalties	2769000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	366000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-956000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2694000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	690000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2281000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-55000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2185000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-520000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16592000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3208000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	615000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4000	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2020Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	3000	USD
CY2021Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	19944000	USD
CY2020Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	-0	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20559000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1000	USD
CY2021Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1649000	USD
CY2020Q1	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	10349000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	231000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	18000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	67592000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	19542000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	30441000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	16333000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	126870000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13526000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	157311000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	29859000	USD
CY2021Q1	vxrt	Issuance Of Warrants To Placement Agents Designees IssuanceOfWarrantsToPlacementAgentsDesignees	0	USD
CY2020Q1	vxrt	Issuance Of Warrants To Placement Agents Designees IssuanceOfWarrantsToPlacementAgentsDesignees	453000	USD
CY2021Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	303000	USD
CY2020Q1	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	0	USD
CY2020Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000
CY2020Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000
CY2021Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	pure
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>Use of Estimates</b> – The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Actual results and outcomes could differ from these estimates and assumptions.</p> <p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"> </p>
CY2021Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-family: "Times New Roman", Times, serif; font-size: 10pt; margin: 0pt; text-align: justify;"><b>Concentration of Credit Risk</b> – Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash, cash equivalents, available-for-sale investments and accounts receivable. The Company places its cash, cash equivalents and available-for-sale investments at financial institutions that management believes are of high credit quality. The Company is exposed to credit risk in the event of default by the financial institutions holding the cash and cash equivalents to the extent such amounts are in excess of the federally insured limits. The Company has <em style="font: inherit;">not</em> experienced any losses on its deposits since inception.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">The primary focus of the Company’s investment strategy is to preserve capital and meet liquidity requirements. The Company’s investment policy addresses the level of credit exposure by limiting the concentration in any <em style="font: inherit;">one</em> corporate issuer or sector and establishing a minimum allowable credit rating. The Company generally requires <em style="font: inherit;">no</em> collateral from its customers.</p> <p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;"> </p>
CY2021Q1	us-gaap	Investments And Cash InvestmentsAndCash	177255000	USD
CY2021Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	5000	USD
CY2021Q1	vxrt	Investments And Cash Fair Value Disclosure InvestmentsAndCashFairValueDisclosure	177250000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	157311000	USD
CY2021Q1	us-gaap	Short Term Investments ShortTermInvestments	13385000	USD
CY2021Q1	us-gaap	Long Term Investments LongTermInvestments	6554000	USD
CY2020Q4	us-gaap	Cash Cash	66865000	USD
CY2020Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	60005000	USD
CY2020Q4	us-gaap	Marketable Securities MarketableSecurities	0	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	700000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	334000	USD
CY2021Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2893000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2053000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	648000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	573000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2245000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1480000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	75000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	19000	USD
CY2021Q1	vxrt	Impairment Of Property And Equipment ImpairmentOfPropertyAndEquipment	0	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6350000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6838000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	20380000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	20380000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5452000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	5019000	USD
CY2021Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	14928000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	15361000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	433000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	433000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1299000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1731000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1732000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1732000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1731000	USD
CY2021Q1	vxrt	Finitelived Intangible Asset Expected Amortization After Year Four FinitelivedIntangibleAssetExpectedAmortizationAfterYearFour	6703000	USD
CY2021Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	14928000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1044000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1618000	USD
CY2021Q1	vxrt	Accrued Clinical And Manufacturing Expenses Current AccruedClinicalAndManufacturingExpensesCurrent	889000	USD
CY2020Q4	vxrt	Accrued Clinical And Manufacturing Expenses Current AccruedClinicalAndManufacturingExpensesCurrent	1772000	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	906000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	777000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	337000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	632000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3176000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4799000	USD
CY2021Q1	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	232000	USD
CY2020Q4	vxrt	Contract With Customer Asset Revenue Recognized ContractWithCustomerAssetRevenueRecognized	219000	USD
CY2021Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	USD
CY2020Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	13000	USD
CY2021Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0992	pure
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y11M15D
CY2021Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	6634000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2006000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4628000	USD
CY2021Q1	vxrt	Lessee Finance Lease Number Of Leases LesseeFinanceLeaseNumberOfLeases	0	pure
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1887000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1801000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1585000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1641000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1112000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8026000	USD
CY2021Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1392000	USD
CY2021Q1	us-gaap	Short Term Lease Commitment Amount ShortTermLeaseCommitmentAmount	0	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	662000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	189000	USD
CY2021Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	60000	USD
CY2020Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	3000	USD
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	293000	USD
CY2020Q1	us-gaap	Variable Lease Cost VariableLeaseCost	11000	USD
CY2021Q1	us-gaap	Sublease Income SubleaseIncome	36000	USD
CY2020Q1	us-gaap	Sublease Income SubleaseIncome	54000	USD
CY2021Q1	us-gaap	Lease Cost LeaseCost	979000	USD
CY2020Q1	us-gaap	Lease Cost LeaseCost	149000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	934000	USD
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	237000	USD
CY2021Q1	us-gaap	Purchase Obligation PurchaseObligation	26800000	USD
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q1	us-gaap	Dividends Dividends	0	USD
CY2021Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8246279
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	9288870
CY2021Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	414252
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1230863
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6813033
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.70
CY2021Q1	vxrt	Share Based Compensation Arrangement By Share Based Payment Award Shares Available For Grant Decrease From Grants ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesAvailableForGrantDecreaseFromGrants	1163000
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1163000
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.27
CY2021Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	207730
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.11
CY2021Q1	vxrt	Share Based Compensation Arrangement By Share Based Payment Award Canceled ShareBasedCompensationArrangementByShareBasedPaymentAwardCanceled	0
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	4139
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	5.17
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	67863
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7764164
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.28
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7764164
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.28
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y10M28D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	23500000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3007780
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.65
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y5M23D
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	11300000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	231000	USD
CY2021Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	207730
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	1100000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	18000	USD
CY2020Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	23606
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	25000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-16007000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-1297000	USD
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	115422628
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	60677145
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2021Q1	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7457452
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	34833292

Files In Submission

Name	View Source	Status
0001437749-21-011133-index-headers.html	Edgar Link	pending
0001437749-21-011133-index.html	Edgar Link	pending
0001437749-21-011133.txt	Edgar Link	pending
0001437749-21-011133-xbrl.zip	Edgar Link	pending
ex_235704.htm	Edgar Link	pending
ex_235705.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pipelineqone.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vxrt-20210331.xsd	Edgar Link	pending
vxrt-20210331_cal.xml	Edgar Link	unprocessable
vxrt-20210331_def.xml	Edgar Link	unprocessable
vxrt-20210331_lab.xml	Edgar Link	unprocessable
vxrt-20210331_pre.xml	Edgar Link	unprocessable
vxrt20210331_10q.htm	Edgar Link	pending
vxrt20210331_10q_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VXRT
Vaxart, Inc. Stock $vxrt

2021 Q1 Form 10-Q Financial Statement

#000143774921011133 Filed on May 06, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VXRT Vaxart, Inc. Stock $vxrt

2021 Q1 Form 10-Q Financial Statement

#000143774921011133 Filed on May 06, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VXRT
Vaxart, Inc. Stock $vxrt